SOUTH CAROLINA – August 12, 2024 – Nephron Pharmaceuticals Corporation proudly announces a significant investment in its manufacturing capabilities with the launch of a new Rommelag Blow-Fill-Seal (BFS) production line. This new line, a $10 million expansion, adds a new presentation, BFS IV bottles, to the existing BFS lineup—respiratory ampules, injection vials, and ophthalmics—that Nephron offers. This will allow medications previously filled in traditional IV bags to be produced more efficiently, reducing wait times and costs.
Capabilities will initially include 250mL IV bottles, with capacity up to 2,000 mL possible. The first production lots on the new line will be allocated to Nephron 503B Outsourcing Facility as it works tirelessly to fill FDA drug shortage needs.
“The launch of our new BFS IV Bottle line is the latest embodiment of the Transformation, Execution, and Trust that drives our Quality First Culture,” said Lou Kennedy, CEO and Owner of Nephron. “We transformed our world-class manufacturing facility once again, investing in new manufacturing capacity on the latest German-engineered Rommelag BFS machinery. Our teams, from vendor auditors to engineers to quality assurance, executed this project with precision and dedication. Because at the end of the day we know that our relationships with customers, and ultimately patients, are built on trust.”
The first product being manufactured on the new line is Fentanyl Citrate in 0.9% Sodium Chloride Injection, USP 2500 mcg/250 mL (10 mcg/mL*). This introduction comes at a crucial time, providing healthcare providers with a reliable source of essential medications amidst ongoing shortages. It is now available for order directly from Nephron for registered customers on the ordering portal. To set up an account for your facility, or to place an order for this product, please contact Nephron at 1-800-443-4313.
About Nephron Pharmaceuticals Corporation: A West Columbia, S.C.-based company, Nephron develops and produces safe, affordable generic inhalation solutions and suspension products. The company also operates an industry-leading 503B Outsourcing Facility division, which produces pre-filled sterile syringes, luer-lock vials, IV bottles, and IV bags for hospitals across America, in an effort to alleviate drug shortage needs. For more information, please visit www.nephronpharm.com.
Contact: Nephron Pharmaceuticals Corporation customerservice@nephronpharm.com 1-800-443-4313